12 July 2023 - Following dossier submission in April 2023, the regulatory agencies have now accepted the dossier for review. ...
11 July 2023 - Express Scripts will include Cyltezo and both Sandoz products (Hyrimoz and unbranded adalimumab-adaz) – inflammatory disease biosimilars ...
3 July 2023 - CMS grants Fresenius Kabi permanent, product-specific Q Code for Idacio (adalimumab-aacf). ...
3 July 2023 - Biocon Biologics today announced that Hulio (adalimumab-fkjp) injection, a biosimilar to Humira (adalimumab), is now available ...
1 July 2023 - Individualised patient support program “Hadlima For You” available including co-pay support. ...
1 July 2023 - Cyltezo is the only adalimumab biosimilar with Phase 3 comparative clinical studies in rheumatoid arthritis, plaque ...
3 July 2023 - Celltrion USA today announced the launch of Yuflyma (adalimumab-aaty), a high concentration (100 mg/mL) and citrate-free formulation ...
30 June 2023 - The biopharmaceutical company now covers ophthalmology as well as auto-immune disease and cancer medicine. ...
1 July 2023 - Hyrimoz (adalimumab-adaz) high concentration formulation biosimilar offers US patients reduced injection volume in citrate free formulation. ...
29 June 2023 - Formycon and its license partner Klinge Biopharma announce that the biologics license application for FYB203, a ...
23 June 2023 - Cyltezo will be commercially available in the US on 1 July 2023. ...
21 June 2023 - Xbrane Biopharma today announced the acceptance of the supplemental biologics license application for a Lucentis (ranibizumab) biosimilar ...
16 June 2023 - Coherus BioSciences said on Thursday it had agreed to retract a restraining order against AbbVie as ...
1 June 2023 - YUSIMRY will be available on costplusdrugs.com for $569.27 plus dispensing and shipping fees. ...
1 June 2023 - List price of $995 per carton for two 40 mg/0.8 mL auto-injectors. ...